EntryPoint Capital’s Aspen Aerogels ASPN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$502K Buy
146,673
+36,531
+33% +$123K 0.15% 245
2025
Q4
$312K Buy
110,142
+44,969
+69% +$232K 0.12% 338
2025
Q3
$454K Sell
65,173
-40,606
-38% -$286K 0.18% 201
2025
Q2
$626K Buy
105,779
+40,969
+63% +$236K 0.31% 41
2025
Q1
$414K Buy
64,810
+35,999
+125% +$347K 0.19% 175
2024
Q4
$342K Buy
28,811
+20,670
+254% +$352K 0.14% 291
2024
Q3
$225K Buy
+8,141
New +$204K 0.13% 389

Other funds holding ASPN

EntryPoint Capital's ASPN Position: Q1 2026 in Review

EntryPoint Capital increased its Aspen Aerogels (ASPN) stake by 33% in Q1 2026, buying an estimated $123K and bringing the position to 146,673 shares worth $502K. The position accounts for 0.15% of the portfolio, ranked #245.

EntryPoint Capital first reported a position in ASPN in Q3 2024 and has held it in 7 quarters since. The position peaked at $626K in Q2 2025. 166 funds tracked by Wall St. Rank hold ASPN as of Q1 2026.

  • EntryPoint Capital held 146,673 shares of Aspen Aerogels worth $502K as of Q1 2026.
  • EntryPoint Capital bought 36,531 Aspen Aerogels shares in Q1 2026, an estimated $123K.
  • Aspen Aerogels made up 0.15% of EntryPoint Capital's portfolio in Q1 2026, its #245 holding.
  • EntryPoint Capital first reported a position in Aspen Aerogels in Q3 2024 and has held it in 7 quarters since.
  • EntryPoint Capital's Aspen Aerogels position peaked at $626K in Q2 2025.
  • 166 funds tracked by Wall St. Rank held Aspen Aerogels as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.